

SHIP: trials update

Ian Ford Robertson Centre for Biostatistics and Glasgow Clinical Trials Unit




- Adequacy of routine health data for inclusion as endpoints in trials
 - WOSCOPS adjudicated outcomes vs. record linkage***
 - PROSPER cancers vs. record linkage*
- Additional linkages for WOSCOPS and PROSPER cohorts
 - Extended follow-up of PROSPER***
 - WOSCOPS linkage to HRG data for economics analyses***
 - Biomarker papers using extended outcomes
 - NTBNP in WOSCOPS***
 - BP variability in PROSPER, predictors of BP variability***
- To do
 - WOSCOPS 20 years
 - PROSPER, WOSCOPS linkage to SCI-DC


***Papers in submission or about to be submitted



•Generic data query and analysis tools

- -Standard format to define study
 - CDISC SDTM
 - Standard controlled terminology same for all studies
 - Easy merging of data
 - Standard, validated eCRF screens
 - Reusable data validations, statistical analysis, reports
- Trial recruitment and feasibility query tool
 - Investigate study feasibility
 - Identify potential participants in primary/secondary care
- Pilot of DataSHIELD implementation with Glasgow e-science hub









Example: WOSCOPS economics analysis



PCI/CABG – CI
























- Treatment of 1000 patients for 5 years with pravastatin 40mg will, over 15 years:
 - -Save the NHS £710,000
 - -Gain 136 QALYs
 - -Save 1836 days in hospital




Cost Effectiveness

Acute CVD costs, on-costs, treatment and monitoring costs Cumulative Mean Cost Difference with 95% CI (Pravastatin - Placebo, £M/1000 people)



Cumulative Mean QALY Difference with 95% CI (Pravastatin - Placebo, /1000 people)



Years Since Randomisation



Cost Effectiveness

